Primary central nervous system effusion plasmablastic lymphoma in immunocompromised patient: A rare phenomenon

Brij Mohan Singh, Sushma Belurkar, Arijit Bishnu, Tanvi Shetty, P. Pavithra

Research output: Contribution to journalArticle

Abstract

Primary effusion lymphoma (PEL) is an aggressive neoplasm with a high rate of fatality. PEL cells are known to have morphological diversities, which range from immunoblastic or plasmablastic to anaplastic. Most of these cases are described in immunocompromised as well as immunocompetent patients. Plasmablastic lymphoma remains a diagnostic challenge, especially when encountered with the presentation as PEL. In spite of therapeutic advances, PEL remains an aggressive disease with a high rate of fatality. We describe one case of this extremely rare neoplasm in an immunocompromised patient presenting in the form of primary central nervous system effusion plasmablastic lymphoma. To the best of our knowledge, this is the first case ever been reported in the literature.

Original languageEnglish
Pages (from-to)6-7
Number of pages2
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume11
Issue number8
DOIs
Publication statusPublished - 01-01-2018

Fingerprint

Primary Effusion Lymphoma
Immunocompromised Host
Central Nervous System
Neoplasms
Plasmablastic Lymphoma

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{44fd1972f91a47f98868e502bbe55691,
title = "Primary central nervous system effusion plasmablastic lymphoma in immunocompromised patient: A rare phenomenon",
abstract = "Primary effusion lymphoma (PEL) is an aggressive neoplasm with a high rate of fatality. PEL cells are known to have morphological diversities, which range from immunoblastic or plasmablastic to anaplastic. Most of these cases are described in immunocompromised as well as immunocompetent patients. Plasmablastic lymphoma remains a diagnostic challenge, especially when encountered with the presentation as PEL. In spite of therapeutic advances, PEL remains an aggressive disease with a high rate of fatality. We describe one case of this extremely rare neoplasm in an immunocompromised patient presenting in the form of primary central nervous system effusion plasmablastic lymphoma. To the best of our knowledge, this is the first case ever been reported in the literature.",
author = "Singh, {Brij Mohan} and Sushma Belurkar and Arijit Bishnu and Tanvi Shetty and P. Pavithra",
year = "2018",
month = "1",
day = "1",
doi = "10.22159/ajpcr.2018.v11i8.24754",
language = "English",
volume = "11",
pages = "6--7",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "8",

}

Primary central nervous system effusion plasmablastic lymphoma in immunocompromised patient : A rare phenomenon. / Singh, Brij Mohan; Belurkar, Sushma; Bishnu, Arijit; Shetty, Tanvi; Pavithra, P.

In: Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, No. 8, 01.01.2018, p. 6-7.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Primary central nervous system effusion plasmablastic lymphoma in immunocompromised patient

T2 - A rare phenomenon

AU - Singh, Brij Mohan

AU - Belurkar, Sushma

AU - Bishnu, Arijit

AU - Shetty, Tanvi

AU - Pavithra, P.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Primary effusion lymphoma (PEL) is an aggressive neoplasm with a high rate of fatality. PEL cells are known to have morphological diversities, which range from immunoblastic or plasmablastic to anaplastic. Most of these cases are described in immunocompromised as well as immunocompetent patients. Plasmablastic lymphoma remains a diagnostic challenge, especially when encountered with the presentation as PEL. In spite of therapeutic advances, PEL remains an aggressive disease with a high rate of fatality. We describe one case of this extremely rare neoplasm in an immunocompromised patient presenting in the form of primary central nervous system effusion plasmablastic lymphoma. To the best of our knowledge, this is the first case ever been reported in the literature.

AB - Primary effusion lymphoma (PEL) is an aggressive neoplasm with a high rate of fatality. PEL cells are known to have morphological diversities, which range from immunoblastic or plasmablastic to anaplastic. Most of these cases are described in immunocompromised as well as immunocompetent patients. Plasmablastic lymphoma remains a diagnostic challenge, especially when encountered with the presentation as PEL. In spite of therapeutic advances, PEL remains an aggressive disease with a high rate of fatality. We describe one case of this extremely rare neoplasm in an immunocompromised patient presenting in the form of primary central nervous system effusion plasmablastic lymphoma. To the best of our knowledge, this is the first case ever been reported in the literature.

UR - http://www.scopus.com/inward/record.url?scp=85051271662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051271662&partnerID=8YFLogxK

U2 - 10.22159/ajpcr.2018.v11i8.24754

DO - 10.22159/ajpcr.2018.v11i8.24754

M3 - Article

AN - SCOPUS:85051271662

VL - 11

SP - 6

EP - 7

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 8

ER -